Cardinal Health received a Buy rating due to its defensive business model, strong adjusted EPS growth of 35% in Q3FY26, and strategic moves into specialty healthcare. The company reported 11% revenue growth, though GAAP earnings were pressured by higher costs and special items. Its valuation is premium with a Forward P/E of 21.64x, supported by improving profitability and cash flow. However, future gains depend on maintaining margin improvements amid risks like legal liabilities from opioid litigation, requiring close monitoring of operational efficiency and cash flow management.
The global gauze bandage rolls market, valued at $1.96 billion in 2025, is projected to grow to $3.19 billion by 2035 at a CAGR of 4.97%. Growth is fueled by increasing surgeries, chronic wound care needs, and demand for advanced antimicrobial produc...
The global gauze bandage rolls market, valued at $1.96 billion in 2025, is projected to grow to $3.19 billion by 2035 at a CAGR of 4.97%. Growth is driven by increased surgeries, chronic wounds, and demand for advanced antimicrobial products, especia...
